dupilumab injection
for subcutaneous use Initial U.S. Approval: 2017
DUPIXENT is an interleukin-4 receptor alpha antagonist indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.
Facts about dupilumab injection
Disease Indications- Atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps
Manufacturer-Sanofi, Regeneron Pharmaceuticals
Usage-Intravenous • Injection: 300 mg/2 mL solution in a single-dose pre-filled syringe with needle shield • Injection: 300 mg/2 mL solution in a single-dose pre-filled syringe
Medicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “dupilumab injection” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Contact Info
CORPORATE OFFICE:
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
EMAIL ID:
info@indianpharmanetwork.co.in
FAX NUMBER:
+91-11-26532129
Query For dupilumab injection
Approved accessible "dupilumab injection"
Dupixent (dupilumab) injection, which CDER approved originally in 2017 for atopic dermatitis, was approved in 2022 as the first treatment for eosinophilic esophagitis, a chronic inflammatory disorder in which eosinophils, a type of white blood cell, are found in esophagus tissue, causing difficulty with swallowing and eating.
Dupixent was also approved in 2022 for adults with prurigo nodularis, a chronic skin disorder characterized by hard, extremely itchy bumps known as nodules. Dupixent is the first approved therapy for this disorder.
How can 1 go about obtaining dupilumab injection?
If dupilumab injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
DUPIXENT (dupilumab) injection, for subcutaneous use Initial U.S. Approval: 2017
References
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa
Indian Pharma Network
Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398
Free Customer Support
info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in